The Comparative Risk of Serious Adverse Events With Tofacitinib and TNF Inhibitors in Patients With Ulcerative Colitis: The Korean Experience as Revealed by a National Database-Reference-Cited by-同舟云学术

The Comparative Risk of Serious Adverse Events With Tofacitinib and TNF Inhibitors in Patients With Ulcerative Colitis: The Korean Experience as Revealed by a National Database

Published:2022 Issue:16 Volume:37 Page:
ISSN:1011-8934
Container-title:Journal of Korean Medical Science
language:en
Short-container-title:J Korean Med Sci

Author:

Seo Gi Hyeon¹^ORCID,Jung Sung Hoon²^ORCID

Affiliation:

1. Healthcare Review and Assessment Committee, Health Insurance Review and Assessment Service, Wonju, Korea.

2. Department of Internal Medicine, Eunpyeong St. Mary’s Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea.

Funder

Korea Health Industry Development Institute

Publisher

Korean Academy of Medical Sciences

Subject

General Medicine

Link

https://jkms.org/pdf/10.3346/jkms.2022.37.e123

Reference23 articles.

1. Risk and characteristics of tuberculosis after anti-tumor necrosis factor therapy for inflammatory bowel disease: a hospital-based cohort study from Korea

2. Epidemiological trend in inflammatory bowel disease in Taiwan from 2001 to 2015: a nationwide populationbased study

3. The first step to unveil the epidemiology of inflammatory bowel disease in Central Asia

4. Tofacitinib, an Oral Janus Kinase Inhibitor, in Active Ulcerative Colitis

5. Tofacitinib as Induction and Maintenance Therapy for Ulcerative Colitis

Cited by 8 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Preventing and managing cardiovascular events in patients with inflammatory bowel diseases treated with small-molecule drugs, an international Delphi consensus;Digestive and Liver Disease;2024-08

2. Analysis of tofacitinib safety in ulcerative colitis from the completed global clinical developmental program up to 9.2 years of drug exposure;United European Gastroenterology Journal;2024-05-22

3. Cardiovascular implications of inflammatory bowel disease: An updated review;World Journal of Cardiology;2023-11-26

4. Risk of venous thromboembolism in Korean patients with rheumatoid arthritis treated with Janus kinase inhibitors: A nationwide population-based study;Seminars in Arthritis and Rheumatism;2023-08

5. Risk of all-cause and cause-specific mortality associated with immune-mediated inflammatory diseases in Korea;Frontiers in Medicine;2023-06-20